mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.025 |
0.4 |
mRNA |
tivozanib |
CTRPv2 |
pan-cancer |
AAC |
-0.028 |
0.4 |
mRNA |
JQ-1 |
CTRPv2 |
pan-cancer |
AAC |
0.024 |
0.4 |
mRNA |
semagacestat |
CTRPv2 |
pan-cancer |
AAC |
-0.029 |
0.4 |
mRNA |
BRD-M00053801 |
CTRPv2 |
pan-cancer |
AAC |
-0.036 |
0.4 |
mRNA |
selumetinib:JQ-1 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.026 |
0.4 |
mRNA |
vorinostat:carboplatin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.026 |
0.4 |
mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
0.021 |
0.4 |
mRNA |
isoliquiritigenin |
CTRPv2 |
pan-cancer |
AAC |
0.052 |
0.4 |
mRNA |
SR8278 |
CTRPv2 |
pan-cancer |
AAC |
0.097 |
0.4 |